TAIHO ONCOLOGY

The company specializes in the development and commercialization of orally administered anti-cancer agents for various tumor types. Taiho Oncology has a robust pipeline of small molecule clinical candidates targeting solid tumor and hematological malignancies, with additional candidates in pre-clinical development. Taiho Oncology is a subsidiary of Taiho Pharmaceutical Co., Ltd. which is part of Otsuka Holdings Co., Ltd. Taiho Oncology is headquartered in Princeton, New Jersey and oversees its parent company's European and Canadian operations, which are located in Zug, Switzerland and Oakville, Ontario, Canada... Taiho Oncology, Inc. is the U.S. subsidiary of Taiho Pharmaceutical Co., Ltd., and an indirect subsidiary of Otsuka Holdings Co., Ltd., which contains more than 180 companies, with over 47,000 employees, in 30 countries worldwide. The Otsuka Group of companies, whose origins date back to 1921, aims to contribute to the health of people around the world. Taiho Oncology Inc. is..

Also known as: Taiho Oncology Europe GmbH, TAIHO ONCOLOGY, INC., Taiho Pharma Asia Pacific PTE. LTD., Taiho Pharma Canada, Inc., Taiho Pharma Europe Limited, Taiho Pharmaceutical Co., Ltd., Taiho Pharmaceutical Group, Taiho Ventures, LLC

Primary location: Princeton United States